EUVIMEDEUVIMED entdecken
Crossref

Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials

Ian A Scott

Age and Ageing · 2024

DOI: 10.1093/ageing/afae023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Age and Ageing, 2024. Verfasst von Ian A Scott. Beteiligte Einrichtung: Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent phase 3 randomised controlled trials of amyloid-targeting monoclonal antibodies in people with pre-clinical or early Alzheimer disease have reported positive results, raising hope of finally having disease-modifying drugs. Given their far-reaching implications for clinical practice, the methods and findings of these trials, and the disease causation theory underpinning the mechanism of drug action, need to be critically appraised. Key considerations are the representativeness of trial populations; balance of prognostic factors at baseline; psychometric properties and minimal clinically important differences of the primary efficacy outcome measures; level of study fidelity; consistency of subgroup analyses; replication of findings in similar trials; sponsor role and potential conflicts of interest; consistency of results with disease causation theory; cost and resource estimates; and alternative prevention and treatment strategies. In this commentary, we show shortcomings in each of these areas and conclude that monoclonal antibody treatment for early Alzheimer disease is lacking high-quality evidence of clinically meaningful impacts at an affordable cost.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntibodies, MonoclonalHumansTreatment OutcomeResearch DesignRandomized Controlled Trials as TopicAmyloid beta-PeptidesDrug CostsClinical Trials, Phase III as TopicCost-Benefit AnalysisEvidence-Based Medicine

Stichwörter der Autor:innen

Alzheimer diseaseefficacymonoclonal antibodyolder peoplerandomised trials

Substanzen

Antibodies, MonoclonalAmyloid beta-Peptides

Autor:innen und Institutionen

  • Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.
  • Department of Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Brisbane, QLD, Australia.

Zitieren

APA

Scott, I. A. (2024). Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials. Age and Ageing. https://doi.org/10.1093/ageing/afae023

Vancouver

Scott IA. Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials. Age and Ageing. 2024. doi:10.1093/ageing/afae023

BibTeX
@article{Scott2024,
  author = {Scott, Ian A},
  title = {Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials},
  journal = {Age and Ageing},
  year = {2024},
  doi = {10.1093/ageing/afae023}
}
Kostenlos starten →